A prospective, interventional study of efficacy and safety of erenumab (70 and 140 mg) in a real-life scenario
Latest Information Update: 07 Jun 2021
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2021 New trial record